CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 64 enrolled
Drug / intervention
Hydrochlorothiazide (HCTZ) +3 moredrug
Likely dose
Hydrochlorothiazide (HCTZ) 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00871871
NCT00871871Phase 1Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled, 2-Part Study to Evaluate the Multiple Dose Effects of Hydrochlorothiazide and Isosorbide Mononitrate on Glucose Homeostasis in Obese Patients With Hypertension

Merck Sharp & Dohme LLC·interventional·Posted Mar 30, 2009·Updated Jul 28, 2015

In Brief

A Phase 1 clinical trial evaluating Hydrochlorothiazide (HCTZ), Comparator: Placebo to HCTZ, and 2 other interventions for Hypertension. Completed, enrolled 64 participants.

Detailed Summary

This study will measure and compare changes in insulin production and sensitivity using the hyperglycemic clamp technique in obese patients with impaired glucose tolerance and hypertension treated with placebo, isosorbide mononitrate (ISMN) or hydrochlorothiazide (HCTZ).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 30, 2009
Enrollment StartMar 1, 2009
Primary CompletionFeb 1, 2010
Study CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.3 years ago

Interventions

Hydrochlorothiazide (HCTZ)drug

HCTZ 50 mg (two 25 mg capsules) once daily for 4 weeks per treatment period.

Comparator: Placebo to HCTZdrug

Placebo to HCTZ two 0 mg capsules once daily for 4 weeks per treatment period

Isosorbide mononitrate (ISMN)drug

ISMN 60 mg extended release capsule once daily for 4 weeks per treatment period

Comparator: Placebo to ISMNdrug

Placebo to ISMN 0 mg capsule once daily for 4 weeks per treatment period